These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 27510230)

  • 1. Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma.
    Swamy SG; Kameshwar VH; Shubha PB; Looi CY; Shanmugam MK; Arfuso F; Dharmarajan A; Sethi G; Shivananju NS; Bishayee A
    Target Oncol; 2017 Feb; 12(1):1-10. PubMed ID: 27510230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular targeted therapy for hepatocellular carcinoma: current and future.
    Shin JW; Chung YH
    World J Gastroenterol; 2013 Oct; 19(37):6144-55. PubMed ID: 24115810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benzylidene-indolinones are effective as multi-targeted kinase inhibitor therapeutics against hepatocellular carcinoma.
    Ho HK; Chua BT; Wong W; Lim KS; Teo V; Ong HT; Chen X; Zhang W; Hui KM; Go ML; Ullrich A
    Mol Oncol; 2014 Oct; 8(7):1266-77. PubMed ID: 24839937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapy of hepatocellular cancer.
    Wysocki PJ
    Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia inducible factor in hepatocellular carcinoma: A therapeutic target.
    Lin D; Wu J
    World J Gastroenterol; 2015 Nov; 21(42):12171-8. PubMed ID: 26576101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical Systemic Therapies for Hepatocellular Carcinoma: Clinical Perspectives and Safety Profile.
    Facciorusso A; Antonino M; Del Prete V; Amoruso A; Neve V; Barone M
    Curr Drug Saf; 2015; 10(3):202-7. PubMed ID: 25994808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced hepatocellular carcinoma. Review of targeted molecular drugs.
    Alves RC; Alves D; Guz B; Matos C; Viana M; Harriz M; Terrabuio D; Kondo M; Gampel O; Polletti P
    Ann Hepatol; 2011; 10(1):21-7. PubMed ID: 21301005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
    Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
    Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting tyrosine kinase receptors in hepatocellular carcinoma.
    Muntané J; De la Rosa AJ; Docobo F; García-Carbonero R; Padillo FJ
    Curr Cancer Drug Targets; 2013 Mar; 13(3):300-12. PubMed ID: 23016985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current status of molecular targeted therapies in hepatocellular carcinoma].
    Suh SJ; Yim HJ
    Korean J Gastroenterol; 2013 Mar; 61(3):136-46. PubMed ID: 23575232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deregulation of signaling pathways involved in sorafenib resistance of hepatocellular carcinoma.
    Makarova AS; Lazarevich NL
    Klin Lab Diagn; 2013 Oct; (10):66-8, 34-7. PubMed ID: 24640100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapy for hepatocellular carcinoma: novel agents on the horizon.
    Cervello M; McCubrey JA; Cusimano A; Lampiasi N; Azzolina A; Montalto G
    Oncotarget; 2012 Mar; 3(3):236-60. PubMed ID: 22470194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved chemotherapy for hepatocellular carcinoma.
    Cao H; Phan H; Yang LX
    Anticancer Res; 2012 Apr; 32(4):1379-86. PubMed ID: 22493374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line.
    Wang W; Xu B; Li Q; Jiang D; Yan S
    Mol Med Rep; 2018 Apr; 17(4):6185-6193. PubMed ID: 29484394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple Roles of Autophagy in the Sorafenib Resistance of Hepatocellular Carcinoma.
    Sun T; Liu H; Ming L
    Cell Physiol Biochem; 2017; 44(2):716-727. PubMed ID: 29169150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging targeted strategies in advanced hepatocellular carcinoma.
    Finn RS
    Semin Liver Dis; 2013 Feb; 33 Suppl 1():S11-9. PubMed ID: 23457035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of microRNAs in the development of hepatocellular carcinoma and acquired drug resistance.
    Tricoli L; Niture S; Chimeh U; Kumar D
    Front Biosci (Landmark Ed); 2019 Jan; 24(3):545-554. PubMed ID: 30468672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.
    Zhu AX
    Expert Opin Investig Drugs; 2010 May; 19(5):663-72. PubMed ID: 20367287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
    De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
    World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving molecular mechanism-based strategies for control of hepatocellular carcinoma.
    Sato K; Mori M
    Curr Med Chem; 2011; 18(28):4375-88. PubMed ID: 21861817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.